NCT03929029 2026-01-05
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
11 trialsNCT06218511 2025-12-22
A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)
National Cancer Institute, Naples
Phase 1 Active not recruiting
NCT04106115 2024-12-04
DURANCE
University College, London
Phase 1/2 Recruiting
NCT00616941 2022-10-12
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT01810016 2022-10-12
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT00112242 2020-06-18
Immunotherapy of Stage III/IV Melanoma Patients
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT01308294 2020-06-11
LAG-3/IMP321
Centre Hospitalier Universitaire Vaudois
Phase 1/2 Terminated
NCT02452775 2020-04-24
Autologous OC-L Vaccine and Ovarian Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Terminated
NCT01079741 2018-02-13
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT00935545 2016-01-26
Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors
NYU Langone Health
Phase 1 Completed
NCT00665002 2015-02-27
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed